Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT00434239

Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia

A Pilot Study of the Combination of Lenalidomide (Revlimid®) With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor (rhSCF; Ancestim) for Myelodysplasia.

Sponsor: Celgene Corporation

Conditions Myelodysplasia

Interventions Lenalidomide + Ancestim

Updated 6 times since 2017 Last updated: Jan 8, 2013 Started: Feb 28, 2007 Primary completion: May 31, 2011 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Myelodysplasia, this trial is ongoing. The trial is conducted by Celgene Corporation and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Unknown Status EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status Phase 0

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Peter MacCallum Cancer Centre, Australia

Data source: Peter MacCallum Cancer Centre, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• East Melbourne, Australia